| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
RBL-2H3 cells remain viable in the presence of narirutin (200 μM, 20 h).
In RBL-2H3 cells, narirutin (25 μM, 2.5 h) inhibits the release of β-hex, histamine, IL-4, and TNF-a, with levels below 40%. [3].
|
|---|---|
| ln Vivo |
Mice challenged with OVA have lower peripheral blood eosinophil counts when given nerirutin (10 mg/kg, p.o.)
The OVA-induced increase in IL-4 is blocked by narirutin (10 mg/kg, p.o. ), but the increase in IL-5 is unaffected [2].
|
| Animal Protocol |
Animal Model: Allergic asthma female NC/Nga mice model[2]
Dosage: 0.1, 1 or 10 mg/kg Administration: Orally, 7d Result: Reduced eosinophil counts in peripheral blood. Blocked the OVA-induced increase in IL-4. Female NC/Nga mice (6-8 weeks old) were used. Mice were immunized intraperitoneally on Day 0 and Day 7 with 100 μg ovalbumin (OVA) plus 1.6 mg aluminum hydroxide in 200 μL sterile saline. Non-sensitized controls received only aluminum hydroxide in saline. On Days 14, 15, and 16, sensitized mice were exposed to aerosolized OVA (10 mg/mL in saline) for 10 min each day; non-sensitized mice were exposed to saline only. Narirutin was administered orally at doses of 0.1, 1, or 10 mg/kg body weight in sterile water (20 μL volume per mouse) daily from Day 7 to Day 16. Control groups received sterile water only. Mice were sacrificed 24 h after the last aerosol challenge (Day 17). [2] |
| References |
|
| Additional Infomation |
Naringin is a disaccharide derivative formed by the substitution of (S)-naringenin at the 7-position via a glycosidic bond with a 6-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl group. It possesses anti-inflammatory, antioxidant, and metabolic activities. Naringin is a disaccharide derivative belonging to the dihydroxyflavanone, 4'-hydroxyflavanone, (2S)-flavan-4-one, and rutin glycoside classes. Its function is related to (S)-naringenin. Naringin has been reported in citrus fruits (Citrus sulcata), citrus fruits (Citrus reticulata), and other organisms with relevant data. See also: Orange peel (partial).
|
| Molecular Formula |
C27H32O14
|
|---|---|
| Molecular Weight |
580.539
|
| Exact Mass |
580.179
|
| Elemental Analysis |
C, 55.86; H, 5.56; O, 38.58
|
| CAS # |
14259-46-2
|
| Related CAS # |
Isonaringin;108815-81-2
|
| PubChem CID |
442431
|
| Appearance |
Solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
924.3±65.0 °C at 760 mmHg
|
| Melting Point |
152-190ºC
|
| Flash Point |
307.3±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.708
|
| LogP |
2.07
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
41
|
| Complexity |
884
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
O1[C@]([H])([C@@]([H])([C@]([H])([C@@]([H])([C@@]1([H])C([H])([H])O[C@@]1([H])[C@@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])[H])O1)O[H])O[H])O[H])O[H])O[H])O[H])OC1=C([H])C(=C2C(C([H])([H])[C@@]([H])(C3C([H])=C([H])C(=C([H])C=3[H])O[H])OC2=C1[H])=O)O[H]
|
| InChi Key |
HXTFHSYLYXVTHC-AJHDJQPGSA-N
|
| InChi Code |
InChI=1S/C27H32O14/c1-10-20(31)22(33)24(35)26(38-10)37-9-18-21(32)23(34)25(36)27(41-18)39-13-6-14(29)19-15(30)8-16(40-17(19)7-13)11-2-4-12(28)5-3-11/h2-7,10,16,18,20-29,31-36H,8-9H2,1H3/t10-,16-,18+,20-,21+,22+,23-,24+,25+,26+,27+/m0/s1
|
| Chemical Name |
(S)-5-hydroxy-2-(4-hydroxyphenyl)-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)chroman-4-one
|
| Synonyms |
Naringenin 7-beta-rutinoside, Naringenin 7-O-rutinoside, (2S)-Narirutin;Isonaringenin, Isonaringin
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100~125 mg/mL ( 172.25~215.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (3.58 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.58 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.58 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.08 mg/mL (3.58 mM) Solubility in Formulation 5: 10 mg/mL (17.23 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7225 mL | 8.6127 mL | 17.2253 mL | |
| 5 mM | 0.3445 mL | 1.7225 mL | 3.4451 mL | |
| 10 mM | 0.1723 mL | 0.8613 mL | 1.7225 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04234100 | COMPLETED | Other: Orange juice rich in hesperidin and narirutin | Blood Pressure Hypertension |
Technological Centre of Nutrition and Health, Spain | 2020-02-24 | Not Applicable |
| NCT02380144 | UNKNOWN STATUS | Other: Fresh orange fruit and pasteurized fruit juice | Healthy | University of Hohenheim | 2014-01 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
